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Abstract: Resveratrol is a polyphenolic flavonoid initially identified as a 
phytoalexin and as a major constituent of red wine. However interest in this 
molecule initially developed as a cardioprotective agent and in due course of 
time therapeutic actions came into limelight. This article explores the different 
therapeutic activities of Resveratrol and highlights their possible mode of 
action responsible for its therapeutic action. It becomes evident from this 
article that Resveratrol has a pharmacological agent that has widespread targets 
and therefore due emphasis on specific biological action need to be addressed 
using medicinal chemistry and quantitative structure activity relationships in 
developing new congeners of Resveratrol to be exploited as drugs. 
Keywords: Resveratrol, phytoalexin, cardiotonic, anti-cancer, anti-oxidant, 
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1. InTRoducTIon
Resveratrol (RSV) or trans-3, 4, 5-trihydroxystilbene (Fig 1.) was originally 
identified as a phytoalexin that in nature protects plants against infection against 
fungi especially Botrytis cinerea (Langcake and Pryce, 1976). Resveratrol 
was identified as a phytochemical since 1940’s when it was first isolated from 
white hellebore (Veratrum grandiflorum O. Loes) and later from the medicinal 
plant Polygonum cupsidatum. Resveratrol is found in at least 72 plant species 
(Dercks and Creasy, 1989) and is formed via a condensation reaction between 
3 molecules of malonyl Coa and 1 molecule of 4-coumaroyl Coa (Soleas et 
al., 1997). Both of these plants find use in the Chinese as well as Japanese 
medicine. Resveratrol was initially identified as an inhibitor of enzymes 
involved in arachidonate metabolism in the leukocytes and of partially purified 




however the content is much less as compared to red wine where it can go up to 
14mg L-1 depending upon the types of grapes used for the wine manufacture. 
In spite of rather a fatty diet the French population has a lower incidence of 
cardiovascular diseases –i.e the French paradox has been attributed to uptake 
of resveratrol by red wine consumption which is a long standing component 
of their diet (Fremont, 2000). Thus this paradox has been the primary driver 
for impetus in research on resveratrol. Hence the present review focuses on the 
naturally occurring polyphenol, Resveratrol for its biological activities as well 
as therapeutic potential 
2. HEAlTH BEnEfITs of REsvERATRol
Incidentally the first use of grape extracts as medicine has been dated 2000 years 
ago as “darakchasava”, a well-known Indian herbal preparation of which the 
main ingredient is Vitis viniferaL (Paul et al., 1999). This ayruvedic medicine 
was prescribed as a cardiotonic. Today a number of therapeutic actions have 
been reported by Resveratrol viz. anti-carcinogenic, anti-inflammatory, anti-
diabetic, anti-microbial, cardioprotective, neuroprotective, anti-ageing, anti-
oxidant and anti-viral activities (Fig.2).
2.1 Resveratrol as Anti- carcinogenic/ chemo preventiveagent
COx primarily catalyze the conversion of arachidonic acid into prostaglandins, 
a proinflammatory substance which can stimulate tumor cell growth and 
suppress immune surveillance (Plescia et al., 1975; goodwin, 1984). COx 
can activate carcinogens to forms that damage genetic material (Zenser et al., 
1983). During screening of plant extracts for their cyclooxygenase (COx) 
inhibitory potential for identification chemo-preventive agents, an extract of 
Cassia quinquangulata Rich. (Leguminosae), collected in Peru, was identified 
as a potent inhibitor wherein resveratrol was identified during the bioassay 
guided isolation. Resveratrol possesses cancer chemo-preventive and cytostatic 
properties via initiation, promotion and progression of carcinogenesis (Jang 
et al., 1997).







Resveratrol also suppresses the proliferation of variety of tumor cells, 
including lymphoid and myeloid cancers; breast, colon, pancreas, stomach, 
prostate, headand neck, ovary, liver, lung and cervical cancers; melanomaand 
muscles. It also induces apoptosis through the caspase-8-dependent pathway 
(receptor mediated) or the caspase-9-dependent pathway (mitochondrial), or 
both. apoptotic and growth inhibitory effects of RSV were observed in human 
B-cell lines which were derived from chronic B-cell malignancies (Roman et 
al., 2002). Fas signaling-dependent apoptosis was triggered by resveratrol in 
HL-60 human leukemia cells (Clement et al., 1998). anti-proliferative effects 
against breast cancer cell lines viz. MCF-7, MCF-10F and MDaMB-231 was 
exhibited by resveratrol which was independent of estrogen receptor status of 
the cells. Wolter et al. (2001) reported that resveratrol inhibited growth and 
proliferation of Caco-2 cells through apoptosis. Human pancreatic cancer cell 
lines PaNC-1 and asPC-1 were inhibited by resveratrol via apoptosis.
Proliferation of androgen dependent and androgen independent prostrate 
cells were suppressed by resveratrol. Thus resveratrol interacts with a variety 
of signaling molecules such as NF-κβ, egr-1; inhibits protein kinases such as 
JNK, MaPK, akt, PKC, PKD and casein kinase II and down-regulates the 
products of genes such as VegF, IL-1, IL-6, IL-8, aR, 5-LOx and COx-2 
while exerting the chemopreventive or anti-cancer action. 
2.2 Resveratrol as a neuroprotective agent
Resveratrol has been reported to be effective in neuroprotective activity which 
is attributed to its anti-oxidant properties. It has been found effective against 




ischemic brain injury and in kainic acid induced brain seizures or neuronal 
damage in rodents (Wang et al., 2002; Wang et al., 2004). 
Resveratrol has an ability to delay the onset of neurodegradation due 
to the formation of β-amyloid plaque formation and oxidative stress. 
alzheimer’s dementia (aD) leads to progressive loss in the memory but 
the etiology of aD is completely unknown but formation of β-amyloid 
plaques have been found to be highly neurotoxic which occurs in aD. 
Oxidative stress serves as a precursor for the amyloid precursor protein 
formation leading to aD (Karuppagounder et al., 2009). Resveratrol 
supplementation has been found to diminish the plaque formation in 
rodent brain in a region specific manner as well as decreased the level of 
glutathione. Marambaud et al. (2005) exhibited that resveratrol in vitro 
removes the amyloid deposits by increased intracellular proteasomal 
activity. Resveratrol supplementation in rodents has also demonstrated the 
ability to prevent kainic acid induced brain seizures (gupta et al., 2002).
Resveratrol has also been tested for its beneficial effects in 6-hydroxydopamine 
induced Parkinson’s rat model. In this model 6-hydroxydopamine induced 
chronic inflammation, mitochondrial dysfunction, and oxidative stress, and 
loss of dopaminergic neurons in the substantia nigra. To overcome these 
effects Resveratrol significantly decreased the level of COx-2, TNF-α mRNa 
and COx-2 protein expression in the substantia nigra (Sun et al., 2010). 
2.3 Resveratrol as an antiviral
Resveratrol exerts an antiviral action against potent DNa as well as RNa 
viruses (Campagna and Rivas, 2010). The very first virus in which resveratrol 
inhibited replication was HSV (Herpes Simplex Virus) 1 and 2 (Docherty 
et al., 1999). It blocks the viral DNa synthesis to inhibit the polyomavirus 
replication (Berardi, et al., 2009). apart from this resveratrol also exhibits anti-
HIV activity, making it a strong lead compound for the development of new 
anti-HIV agents. Resveratrol in a dose dependent fashion also inhibits epstein 
Barr Virus, Human cytomegalovirus and Varicella Zoster Virus (Docherty et 
al., 2006; evers et al., 2004; Kapadia et al., 2002). 
2.4 Resveratrol as an anti-inflammatory agent
The two primary enzymes involved in the synthesis of pro-inflammatory 
mediators are 5-HeTe (5-hydroxy-6, 8, 11, 14-eicosatetranenoic acid), 
thromboxane a2, prostaglandins & HTT (12- hydroxyl-5, 8, 10 - 
heptadecatrienoic acid) are cyclooxygenase and lipoxygenase pathways 
(Cuendet and Pezzuto, 2000). The prostaglandins have been implicated in 







tumorigenesis (gusman et al., 2001). Resveratrol has been found to inhibit 
5- lipoxygenase product 5-HeTe and COx products HHT and thromoboxane 
B2 (Kimura et al., 1985). The COx and LOx inhibitory activities of RSV 
also account for its protective effect against oxidative stress induced death 
of human erythroleukaemia K652 cells (MacCarrone et al., 1999). The anti- 
inflammatory activity has been demonstrated in a rat model of carrageenan 
induced paw edema (gentilli et al., 2001). RSV remarkably inhibits the ROS 
production, release of elastase and β-glucuronidase from neutrophil granules 
and cell surface expression of the β2-integrin MaC-1 upon PMN stimulation 
indicating that RSV elicits an inhibitory action at all physiological phases of 
inflammatory response (Pervaiz, 2003). Resveratrol also has beneficial effect 
on the control of anti-inflammatory disorders such as arthritis and inflammatory 
bowel disease. 
2.5 Resveratrol as an anti-diabetic
Diabetes mellitus is a modern day epidemic which is characterized 
by high blood sugar level which may be due to abnormal insulin 
secretion or insulin receptor or post receptor events affecting the overall 
metabolism of carbohydrates, fats and proteins. Resveratrol has been 
found to improve insulin action in different animal models (Sharma 
et al., 2011). The anti-hyperglycemic and anti-oxidant activity of 
resveratrol has been assessed by its modulatory effects on the activities 
of carbohydrate metabolizing enzymes in the kidney and in the hepatic 
tissues of streptozotocin-nicotinamide induced diabetic rats (Palsamy 
and Subramanian, 2009; Movahed et al., 2013). 
Resveratrol administration also reduced the level of glycosylated 
hemoglobin (Hba
1c
) as well as improved plasma insulin level by stimulating 
β-cells to synthesize more insulin and regulate Hba
1c
formation rate thereby 
exhibiting an insulin mimetic effect ( Su et al., 2006)
. 
2.6 Resveratrol as an anti-oxidant 
The consumption of oxygen in normal functions such as respiration and cell 
mediated immune functions leads to the production of Reactive Oxygen 
Species (ROS). ROS comprises of free radicals such as superoxide anion 
radicals (O
2





) and singlet oxygen (gulcin et al., 2005). as ROS 
are continuously produced during the normal physiological functions of 
the cell they cause peroxidation of lipids in the membranes. They are also 




acids, proteins, carbohydrates apart from damage to DNa. In case of failure 
to effectively scavenge ROS, several diseases are indicated due to damage 
to the biomolecules such as proteins, lipids and nucleic acids (Halliwelland 
gutteridge, 1990). anti-oxidants increasingly find applications in enhancing 
the shelf life and stability of food products and pharmaceuticals as they retard 
lipid peroxidation (Haliwell, 1997). 
Resveratrol has exhibited to have a higher aBTS (2, 2- azinobis 
(3-ethylbenzthiazoline-6-sulfonic acid); DPPH (1, 1,-diphenyl-2-
picrylhydrazyl) and hydroxyl scavenging activity when compared to propyl 
gallate, vitamin C, Vitamin e (Soraeset al., 2003). It also inhibits oxidation 
induced apoptosis in a variety of cell lines such as including Swiss 3T3 
mouse fibroblasts, rat pheochromocytoma (PC12), human peripheral blood 
mononuclear (PBM), and human retinal pigment epithelium(RPe) cells (Jang 
and Surh 2001; Losa 2003; Kutuket al 2004; King et al. 2005). Resveratrol 
has also been found to inhibit the inflammatory cytokines such as tumor 
necrosisfactor-α (TNF-α) and interleukin-1β (IL-1β) (Pendurthiet al., 1999; 
Culpittet al., 2003).
2.6 Resveratrol as a cardioprotective agent
Cardiovascular disease are the leading causes of mortality throughout the world. 
The common risk factors for cardiovascular diseases are hypertension, obesity, 
dyslipidemia, insulin resistance, glucose intolerance and increased oxidative 
stress. a significant observation was the South French population despite high 
fat consumption in their diet and heavy use of tobacco products had a very low 
incidence of cardiovascular disease. This is referred to as French Paradox and 
may be associated with the dietary consumption of red wine which is a dietary 
source of resveratrol and may be associated with the positive cardiovascular 
effects of moderate wine consumption (Constant, 1997). It has been found 
that resveratrol inhibits LDL (low density lipoprotein) oxidation which is the 
key event in the initiation of atherosclerosis (Belguendouz et al., 1997; Zou 
et al., 1999; Zou et al., 2000).The second mechanism by which resveratrol 
acts as a cardioprotective agent is by inhibition of platelet aggregation (Wang 
et al., 2002). Platelet aggregation play a very important role in hemostasis 
bywhich injury in the vascular endothelium is rapidlyrepaired in order not to 
compromise the fluidity ofthe blood. Normally the platelets adhere to sub-
endothelial matrix of damaged vessel then spread over the surface and form 
a thrombus by recruiting the additional platelets. Improper regulation or over 
activity of this repair system leads to pathological thrombosis. During the 
process of atherogenesis an essential requisite is migration and proliferation 







been found to suppress this proliferation of smooth muscle cells as well as 
pulmonary aortic endothelial cells (Zou et.al, 1999 (b); Poussier et al., 2005). 
Resveratrol also possesses vasorelaxation properties. The vasorelaxation 
is mediated in endothelium-intact and endothelium independentaortic rings 
via nitric oxide (NO)-dependent and -independent mechanisms, respectively. 
Resveratrol relaxed the endothelium intact rat aortic rings constricted by 
phenylephrine and potassium chloride via NO release; however, there was no 
vasorelaxation effect with endothelium-independent rings (Orallo et al., 2002). 
The release of NO has also been suggested as a mechanism for the reduction 
of ischemia-reperfusion injury experienced by rat hearts after resveratrol 
treatments (Hung et al., 2000).
apart from the above actions, resveratrol is associated with dose-dependent 
increase in the expression of tumor suppressor gene p53, heat shock protein 
HSP27, quinonereductase 1 and 2, and altered subcellular distribution of nitric 
oxide synthase and apoptosis inducing factor (Wang et al., 2006). all these 
results support that resveratrol acts as a cardioprotective agent by plethora 
of activities which interfere with the events leading to atherosclerosis and 
Coronary heart disease. 
2.7 Phytoesterogenic activity of Resveratrol
Phytoestrogens are non- steroidal compounds which resemble estrogens as 
they bind to estrogen receptors resulting in transcription of estrogen responsive 
genes. Resveratrol is similar to synthetic estrogen diethylstilbestrol (DeS) 
and may possess estrogenic activity. It is also proposed that this estrogenic 
activity of resveratrol provides cardio- protection as well as prevents the risk 
of estrogen dependent cancers. 
Resveratrol has been found to inhibit advanced glycation end products 
(age’S) induced cellular events which are involved in a variety of vascular 
complications (Mizutani et al., 2000). MCF-7, human breast carcinoma cell 
line has been studied for understanding the estrogenic properties of resveratrol. 
Resveratrol stimulates the estrogen regulated progesterone receptor expression 
in MCF-7 (ghem et al., 1997; Lu and Serrero, 1999; Bhat et al. 2001). ghem 
et al., (1997) found that resveratrol exhibited a super agonist property by 
inducing a reporter gene activity 2- to 3- folds greater than estradiol. Both 
cis- and trans- resveratrol exhibited a super agonist activity in MVLN cells, an 
estrogen dependent cell line (Basly et al., 2000). 
estrogenic activity of resveratrol has also been implicated in prevention of 
bone loss in post-menopausal women. Resveratrol enhances the proliferation of 
oestoblastic ML3T3-e1 cells and induces alkaline phosphatase activity which 




treated ovariectomizedratshave been found to have greater femur bone length, 
epiphysis bone mineral density and bone calcium content than ovariectomized 
rats without resveratrol treatment (Liu et al. , 2005)
2.8 Anti-ageing activity of Resveratrol
anti-ageing interventions essentially refer to both cosmetic maintenance of 
age through appropriate healthful appearance as well as stemming up the 
development of degenerative diseases optimizing in the brain as well as in 
other tissues to prolong life. a family of enzymes called Sirtuins specifically 
Sirtuin 1 (SIRT1) possesses anti-ageing action. Resveratrol has been found to 
activate SIRT1 and also exhibits the anti-oxidant effects.
Thus SIRT1 activation leads to modulation of a variety of proteins including 
peroxisome proliferator activated receptor co- activator-1 α, the FOxO family, 
protein kinase B, and NFκβ. SIRT belongs to histone deacetylases (HDaC’s). 
During in vitro screening of SIRT1 activators, Resveratrol was identified as 
the most potent of all the 18 inducers who activity was tested during the assay 
(Baur and Sinclair, 2006; Balan et al., 2008). Resveratrol extends the life 
span in Saccharomyces cerevisiae, Caenorhabditiselegans (Tissenbaum and 
guarente, 2001) and Drosophila melanogaster only of the genes of SIRT2 are 
present in these organisms. Resveratrol has shown to extend the lifespan of 
short lived fish by 59% concomitant with maintenance of learning and motor 
function (Valenzano and Cellerino, 2006; Terzibasi et al., 2007). Resveratrol 
has also been found to be an activator of human SIRT1 (Borra et al., 2005)
2.9 Anti-microbial activity of Resveratrol
Phytoalexins are low molecular weight compounds which exhibit biological 
activity against a range of plant as well as human pathogens (Jeandt et al., 
2002; Mahady, 2006). Resveratrol was initially identified as a phytoalexin 
in Vitis vinifera (grapes) which has been subjected to intensive investigation 
because of multiple implications on human health. as resveratrol possesses 
anti-oxidant properties it is expected that it may also possess antimicrobial 
effects and may be used to prevent microbial infections. Resveratrol has been 
previously reported to possess anti-viral activity. 
Resveratrol has been found to inhibit the growth of Helicobacter pylori 
which is responsible for duodenal ulcer disease, dyspepsia, peptic ulcer and 
gastric B cell lymphoma (Mahady and Pendland, 2000). Resveratrol also 
exhibited a MIC of 200mg/L against Propionibacterium acnes growth which 
is a gram positive, non-spore forming anaerobic bacillus associated with 
acne vulgaris (Docherty et al., 2007). Resveratrol has exhibited a potential 







mentagrophytes, Trichophyton tonsurans, Trichophyton rubrum and 
Epidermatophyton floccosum in a range of 25-50 µg/ ml. Thus there is an 
ample scope of using resveratrol to combat dermatophytic fungal infections 
(Chan, 2002). Resveratrol thus possesses potential to be used as a natural 
antimicrobial for functional as well as therapeutic applications. 
3. concludIng REmARKs 
The body of evidence presented here clearly highlights the potential of 
Resveratrol as a pharmacophore with wide spectrum of targets. However 
it is currently recommended as a Nutritional supplement and not medicine 
due to its multifarious actions. The pharmaceutical industries are much 
interested in development of target specific drugs from Resveratrol and 
therefore requires concerted research efforts in medicinal chemistry 
and quantitative structural activity relationship to develop congeners of 
resveratrol which would work for a specific or targeted activity with least 
side effects.
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